Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats

In vitro pharmacological profile of the A2A receptor antagonist istradefylline

(2013) Mayumi Saki et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Antidepressant-like activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodents

(2013) Koji Yamada et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Differential effects of adenosine A1 receptor on pain-related behavior in normal and nerve-injured rats

(2010) Qing-Juan Gong et al.   BRAIN RESEARCH

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study

(2010) Yoshikuni Mizuno et al.   MOVEMENT DISORDERS

Behavioral animal models of depression

(2010) Hua-Cheng Yan et al.   Neuroscience Bulletin

Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)

(2008) Peter A. LeWitt et al.   ANNALS OF NEUROLOGY

Enhancing brain adenosine signaling with the nucleoside transport blocker NBTI (S-(4-nitrobenzyl)-6-theoinosine) mimics the effects of inescapable shock on later shuttle-escape performance in rats.

(2008) Thomas R. Minor et al.   BEHAVIORAL NEUROSCIENCE

Depressive symptoms in Parkinson’s disease

(2008) M. R. Lemke   EUROPEAN JOURNAL OF NEUROLOGY

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

(2008) M. Stacy et al.   NEUROLOGY

The HPA axis in major depression: classical theories and new developments

(2008) Carmine M. Pariante et al.   TRENDS IN NEUROSCIENCES